Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection. The agent (Tecentriq Hybreza, ...

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The ...

Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for patients with solid tumors. On Dec. 27, 2024, the Food and Drug ...

The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...

Leqembi Iqlik's subcutaneous injection for Alzheimer's disease received FDA approval, based on Phase III trial data showing comparable efficacy to IV dosing. The subcutaneous formulation demonstrated ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately ...